BR9205645A - Derivados de 2,4-diaminoquinazolinas para aumentar a atividade antitumoral - Google Patents

Derivados de 2,4-diaminoquinazolinas para aumentar a atividade antitumoral

Info

Publication number
BR9205645A
BR9205645A BR9205645A BR9205645A BR9205645A BR 9205645 A BR9205645 A BR 9205645A BR 9205645 A BR9205645 A BR 9205645A BR 9205645 A BR9205645 A BR 9205645A BR 9205645 A BR9205645 A BR 9205645A
Authority
BR
Brazil
Prior art keywords
antitumor activity
increase antitumor
diaminoquinazoline derivatives
diaminoquinazoline
derivatives
Prior art date
Application number
BR9205645A
Other languages
English (en)
Inventor
Jotham W Coe
Anton F J Fliri
Takushi Kaneko
Eric R Larson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR9205645A publication Critical patent/BR9205645A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR9205645A 1991-02-20 1992-01-08 Derivados de 2,4-diaminoquinazolinas para aumentar a atividade antitumoral BR9205645A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65792291A 1991-02-20 1991-02-20
PCT/US1992/000028 WO1992014716A1 (en) 1991-02-20 1992-01-08 2,4-diaminoquinazolines derivatives for enhancing antitumor activity

Publications (1)

Publication Number Publication Date
BR9205645A true BR9205645A (pt) 1994-06-07

Family

ID=24639196

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9205645A BR9205645A (pt) 1991-02-20 1992-01-08 Derivados de 2,4-diaminoquinazolinas para aumentar a atividade antitumoral

Country Status (23)

Country Link
EP (1) EP0572437B1 (pt)
JP (1) JPH06500117A (pt)
KR (1) KR930703270A (pt)
CN (1) CN1064271A (pt)
AT (1) ATE121735T1 (pt)
AU (1) AU655798B2 (pt)
BR (1) BR9205645A (pt)
CA (1) CA2101542A1 (pt)
CZ (1) CZ387292A3 (pt)
DE (2) DE9290018U1 (pt)
DK (1) DK0572437T3 (pt)
ES (1) ES2071484T3 (pt)
FI (1) FI933656A (pt)
HU (1) HUT64755A (pt)
IE (1) IE920522A1 (pt)
IL (1) IL100942A0 (pt)
MX (1) MX9200675A (pt)
NO (1) NO932954D0 (pt)
NZ (1) NZ241627A (pt)
PT (1) PT100132A (pt)
WO (1) WO1992014716A1 (pt)
YU (1) YU17092A (pt)
ZA (1) ZA921911B (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
ES2049659B1 (es) * 1992-10-08 1994-10-16 Ici Plc Una composicion farmaceutica a base de derivados de quinazolina con actividad anti-cancerigena.
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9314893D0 (en) * 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
DE4429026C2 (de) * 1994-08-16 1995-11-16 Mueller Wolfgang Inlay-Entfernungsinstrumentarium für Totalendoprothese
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508535D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
DE69613367T2 (de) * 1995-04-27 2002-04-18 Astrazeneca Ab Chinazolin derivate
GB9508537D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
WO1997020822A1 (en) * 1995-12-01 1997-06-12 Novartis Ag Quinazolin-2,4-diazirines as npy receptor antagonist
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
BR9707495A (pt) 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
GB9603097D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
KR100489174B1 (ko) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
GB9607729D0 (en) * 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
AU769222B2 (en) 1999-11-05 2004-01-22 Genzyme Corporation Quinazoline derivatives as VEGF inhibitors
WO2001068615A1 (en) * 2000-03-13 2001-09-20 Chemrx Advanced Technologies, Inc. Quinazoline synthesis
MXPA02009891A (es) 2000-04-07 2003-03-27 Astrazeneca Ab Compuestos de quinazolina.
WO2003055866A1 (en) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
JP5129957B2 (ja) * 2003-07-03 2013-01-30 ミリアド ジェネティクス， インコーポレイテッド カスパーゼの活性化因子およびアポトーシスの誘発因子としての４−アリールアミノ−キナゾリン
JP2007269629A (ja) * 2004-06-21 2007-10-18 Astellas Pharma Inc キナゾリン誘導体
AU2005269974A1 (en) * 2004-07-06 2006-02-09 Angion Biomedica Corporation Quinazoline modulators of hepatocyte growth factor / c-Met activity for the treatment of cancer
AU2006204052A1 (en) * 2005-01-03 2006-07-13 Cytovia, Inc. Method of treating brain cancer
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
CA2592900A1 (en) * 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
WO2007065913A1 (en) * 2005-12-07 2007-06-14 Neurosearch A/S Novel quinazoline-2,4-diamine derivatives and their use as modulators of small-conductance calcium-activated potassium channels
CN101100466B (zh) 2006-07-05 2013-12-25 天津和美生物技术有限公司 不可逆蛋白质酪氨酸磷酰化酶抑制剂及其制备和应用
WO2008086462A2 (en) * 2007-01-11 2008-07-17 Wyeth AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS
WO2009001060A2 (en) * 2007-06-27 2008-12-31 Summit Corporation Plc Use of compounds for preparing anti-tuberculosis agents
CA2798698A1 (en) * 2010-05-07 2011-11-10 Cleave Biosciences, Inc. (Cleave) Methods and compositions for inhibition of the transitional endoplasmic reticulum atpase
US11318137B2 (en) * 2017-05-17 2022-05-03 Vanderbilt University Quinazoline compounds as modulators of Ras signaling

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635979A (en) * 1969-09-29 1972-01-18 Pfizer Certain 6- and/or 7-alkoxy-substituted-2 4-bis(disubstituted amino) quinazolines
IL88507A (en) * 1987-12-03 1993-02-21 Smithkline Beckman Intercredit 2,4-diaminoquinazolines, process for their preparation and pharmaceutical compositions comprising them
AU610328B2 (en) * 1987-12-03 1991-05-16 Smithkline Beckman Intercredit B.V. 2,4- diaminoquinazoline derivatives

Also Published As

Publication number Publication date
HU9302384D0 (en) 1993-11-29
EP0572437A1 (en) 1993-12-08
KR930703270A (ko) 1993-11-29
YU17092A (sh) 1994-12-28
NO932954L (no) 1993-08-19
HUT64755A (en) 1994-02-28
ZA921911B (en) 1993-08-19
EP0572437B1 (en) 1995-04-26
NZ241627A (en) 1993-06-25
DE9290018U1 (de) 1993-10-14
ATE121735T1 (de) 1995-05-15
JPH06500117A (ja) 1994-01-06
AU1184892A (en) 1992-09-15
WO1992014716A1 (en) 1992-09-03
AU655798B2 (en) 1995-01-12
CA2101542A1 (en) 1992-08-21
IE920522A1 (en) 1992-08-26
ES2071484T3 (es) 1995-06-16
FI933656A0 (fi) 1993-08-19
FI933656A (fi) 1993-08-19
DE69202243D1 (de) 1995-06-01
MX9200675A (es) 1992-08-01
NO932954D0 (no) 1993-08-19
PT100132A (pt) 1993-05-31
DE69202243T2 (de) 1995-08-31
CN1064271A (zh) 1992-09-09
IL100942A0 (en) 1992-11-15
CZ387292A3 (en) 1994-04-13
DK0572437T3 (da) 1995-07-03

Similar Documents

Publication Publication Date Title
BR9205645A (pt) Derivados de 2,4-diaminoquinazolinas para aumentar a atividade antitumoral
BR9107070A (pt) Processo para a preparação de derivados de quinazolina uteis para melhorar a atividade antitumoral.
IN170909B (pt)
ES2068714T3 (es) Derivados de pirimidina para aumentar la actividad antitumoral.
ATE311399T1 (de) 2'-deoxy-4'-thioribonucleoside als antivirale und antikrebsmittel
ES2001108A6 (es) Un procedimiento para la preparacion de un derivado de gem-dihalo-1,8-diamino -4 -aza-octano.
FI950101A (fi) 4-oksa-1-atsabisyklo 3,2,0 -7heptanoni-johdannaiset kasvainten vastaisina aineina
CA1265160C (en) GEM-DIHALOGENO- AND GEM-TETRAHALOGENO-1,12-DIAMINO-4,9-DIAZA-DODECANE

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
FC Decision: refusal
FC Decision: refusal